Royal DSM, the Life Sciences and Materials Sciences company, today reported a second quarter EBITDA of €345 million compared to €290 million in Q2 2012 and €311 million in Q1 2013. The improvement compared to Q2 2012 was realized despite a negative caprolactam effect of €20 million and a challenging macro-economic environment, which mainly affected Materials Sciences.

Commenting on the results, Feike Sijbesma, CEO/Chairman of the DSM Managing Board, said: “We are pleased to report that the momentum in our Nutrition business that we saw at the end of Q1 continued into Q2. Nutrition, with its higher profits and healthy margins, is demonstrating the quality of its broad offering across the value chain. Materials Sciences’ profit remained at the same level as last year despite a negative caprolactam impact of €20 million and a challenging market environment.”

“For the rest of this year, we will continue to fully focus on operational performance and on the integration of our acquisitions, ensuring the capture of synergies. In addition, the early successes of our profit improvement initiatives leave us confident that this group-wide program is well on track. We expect strong EBITDA growth in 2013, moving towards €1.4 billion.”

Key figures

Q2 2013

Q2 2012

+/-

in € million

volume

price/mix

exch. rates

other

2,468

2,268

9%

Net sales

6%

-4%

-1%

8%

1,108

899

23%

Nutrition

6%

-3%

-2%

22%

187

182

3%

Pharma

3%

1%

-1%

714

713

0%

Performance Materials

6%

-3%

-2%

-1%

375

389

-4%

Polymer Intermediates

5%

-8%

-1%

37

18

Innovation Center

47

67

Corporate Activities

Q2 2013

Q2 2012

+/-

in € million

H1 2013

H1 2012

+/-

345

290

19%

EBITDA

656

596

10%

249

195

28%

Nutrition

464

387

20%

14

17

-18%

Pharma

22

22

0%

82

77

6%

Performance Materials

162

156

4%

26

30

-13%

Polymer Intermediates

55

99

-44%

-3

-10

Innovation Center

-7

-25

-23

-19

Corporate Activities

-40

-43

156

118

32%

Core net profit

285

267

7%

141

114

24%

Net profit, before exceptional items

262

259

1%

112

41

173%

Net profit, after exceptional items

231

186

24%

0.91

0.71

28%

Core EPS (€/share)

1.67

1.62

3%

0.79

0.67

18%

Net EPS before exceptional items (€/share)

1.49

1.54

-3%

0.62

0.23

170%

Net EPS after exceptional items (€/share)

1.31

1.10

19%

231

197

Cash flow from operations

153

294

168

162

Capital expenditures (cash)

332

288

Net debt

2,266

1,668*

* year-end 2012

You can find the press release in full, including financial statements, below.